| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/16/2013 | CN102871960A Lentinan injection and preparation method thereof |
| 01/16/2013 | CN102871956A Propranolol hydrochloride gel for treating infant superficial hemangioma |
| 01/16/2013 | CN102871951A Hyaluronic acid nano microgel loaded with anti-cancer medicine and preparation method for hyaluronic acid nano microgel |
| 01/16/2013 | CN102871950A 一种熊果酸固体分散体及其制备方法 One kind of ursolic acid solid dispersion and its preparation method |
| 01/16/2013 | CN102441000B Anti-cancer anti-disease buccal tablet |
| 01/16/2013 | CN102357072B Injection preparation of T-2 lienomycin |
| 01/16/2013 | CN102335119B New preparation for chemotherapy on tumor vascular thrombosis mediated by biological effect of ultrasound |
| 01/16/2013 | CN102284010B Composition for treating leukemia, myeloma multiplex and myelodysplastic syndrome |
| 01/16/2013 | CN102276813B Targeting polymer drug carrier containing folic acid and preparation method thereof |
| 01/16/2013 | CN102266291B Preparation method of strychnine immune nanoparticles |
| 01/16/2013 | CN102232946B Use of antrodia camphorata cyclohexenone compound in preparing medicine for inhibiting stomach cancer tumor cell growth |
| 01/16/2013 | CN102228425B Tumor-targeted magnetic hydrogel nanoscale medicine delivery system and construction method and application thereof |
| 01/16/2013 | CN102225054B Preparation carried with particles of antitumor drug and preparation method thereof |
| 01/16/2013 | CN102168058B Anti-tumor targeting engineering bacteria and bacterial agent and method for preparing bacterial agent |
| 01/16/2013 | CN102154218B Hybridoma cell strain 4e9 and monoclonal antibody produced by using hybridoma cell strain 4e9 |
| 01/16/2013 | CN102133404B Tumor targeted therapeutic drug carrier as well as preparation method and application thereof |
| 01/16/2013 | CN102102102B Novel application of hsa-miR-185 |
| 01/16/2013 | CN102093424B Platinum coordination compound of anti-tumor medicaments |
| 01/16/2013 | CN102080085B Human miR-193b antisense nucleotide and application thereof |
| 01/16/2013 | CN102041256B Human miR-486-5p antisense nucleic acid and application thereof |
| 01/16/2013 | CN102006864B Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 01/16/2013 | CN101969961B Combined use of cholestanol derivative |
| 01/16/2013 | CN101948858B RNA (Ribose Nucleic Acid) interference recombination vector of SET (Patient SE Translocation) genes and establishment method and application thereof |
| 01/16/2013 | CN101935295B Method for extracting active ingredients from papaya seeds |
| 01/16/2013 | CN101926844B Stellera chamaejasme L extract and anti-tumor action thereof |
| 01/16/2013 | CN101921236B 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 01/16/2013 | CN101912611B Drug composition with anti-tumor effect |
| 01/16/2013 | CN101899011B Dithiocarbamates compound, preparation method and application thereof |
| 01/16/2013 | CN101891769B Anti-tumor platinum complexes |
| 01/16/2013 | CN101869633B Enteric-coated medicament combination containing epigallocatechin gallate |
| 01/16/2013 | CN101857597B Diethylene triamine pentaacetic acid or ethylene diamine tetraacetic acid or amine triacetic acid modified porphyrin, preparation method and application thereof |
| 01/16/2013 | CN101663033B Triazole derivatives which are SMO antagonists |
| 01/16/2013 | CN101648883B Isoliquiritigenin derivant with antineoplastic activity and synthetic method thereof |
| 01/16/2013 | CN101641365B Novel sulfonated sugar derivative, and use thereof for medicinal agent |
| 01/16/2013 | CN101294164B Expression of recombinant human metaphase factor (rh-Midkine), preparation and application of monoclone antibody |
| 01/16/2013 | CN101170995B 新颖的脂质体组合物 Novel liposome compositions |
| 01/16/2013 | CN101074218B Cephalotamannine derivative, its production, its medicinal composition and use |
| 01/15/2013 | US8354397 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 01/15/2013 | CA2706833C Geranyl compounds |
| 01/15/2013 | CA2706826C Geranyl compounds |
| 01/15/2013 | CA2689092C Raf kinase modulators and methods of use |
| 01/15/2013 | CA2650577C Use of 12-imidazolyl-1-dodecanol or its pharmaceutically acceptable salts for producing a pharmaceutical preparation |
| 01/15/2013 | CA2583375C Regulation of oncogenes by micrornas |
| 01/15/2013 | CA2572971C Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase |
| 01/15/2013 | CA2524161C Pyridinyl acetonitriles |
| 01/15/2013 | CA2460269C Alphavirus replicon vector systems |
| 01/15/2013 | CA2406725C Edg8 receptor, its preparation and use |
| 01/15/2013 | CA2400842C Novel compounds |
| 01/10/2013 | WO2013006864A2 Treating cancer with hsp90 inhibitory compounds |
| 01/10/2013 | WO2013006764A1 Method of treating cholangiocarcinoma and apparatus |
| 01/10/2013 | WO2013006758A1 Diphosphate mimetics and uses thereof |
| 01/10/2013 | WO2013006706A1 P97-antibody conjugates and methods of use |
| 01/10/2013 | WO2013006619A1 Rna-yy1 interactions |
| 01/10/2013 | WO2013006532A1 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| 01/10/2013 | WO2013006490A2 Antibodies that specifically bind to tim3 |
| 01/10/2013 | WO2013006368A1 Combination therapy |
| 01/10/2013 | WO2013006129A1 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
| 01/10/2013 | WO2013005379A1 Photodynamic therapy using photosensitizing agent or 5-aminolevulinic acid |
| 01/10/2013 | WO2013005170A2 Inhibitors of aquaglyceroporins, methods and uses thereof |
| 01/10/2013 | WO2013005154A1 Anticancer agent |
| 01/10/2013 | WO2013005057A1 New compounds |
| 01/10/2013 | WO2013005049A1 N- (2 -aminophenyl) benzamide derivatives as histone deacetylase inhibitors |
| 01/10/2013 | WO2013005041A1 Tricyclic heterocyclic compounds as kinase inhibitors |
| 01/10/2013 | WO2013004984A1 Tricyclic compounds for use as kinase inhibitors |
| 01/10/2013 | WO2013004436A1 Compositions containing broccoli seeds for treating or preventing prostate cancer |
| 01/10/2013 | WO2013004332A1 Substituted azaheterocycles for the treatment of cancer |
| 01/10/2013 | WO2013004145A1 Composition of chinese herbal compound or extract and use thereof |
| 01/10/2013 | WO2013004086A1 Fructosylated mangiferin and preparation method therefor and use thereof |
| 01/10/2013 | WO2013004076A1 Agr2 blocking antibody and use thereof |
| 01/10/2013 | WO2013004075A1 Tumor targeted drug combretastatin a4 derivative |
| 01/10/2013 | WO2013004020A1 Pseudomonas aeruginosa (pa-msha) strain igy and preparation method and use thereof |
| 01/10/2013 | WO2013003987A1 Tumor-targeted tumor necrosis factor-related apoptosis ligand variant and use thereof |
| 01/10/2013 | WO2013003912A1 Cryptate compounds |
| 01/10/2013 | WO2013003895A1 Combination therapy |
| 01/10/2013 | WO2012159006A8 Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof |
| 01/10/2013 | WO2012158818A3 Multi-specific fab fusion proteins and methods of use |
| 01/10/2013 | WO2012158776A3 Combination therapy for treatment of cancer |
| 01/10/2013 | WO2012156756A3 Macrocyclic compounds as protein kinase inhibitors |
| 01/10/2013 | WO2012149416A3 Human myeloid derived suppressor cell cancer markers |
| 01/10/2013 | WO2012149160A3 Viruses modified with unnatural moieties and methods of use thereof |
| 01/10/2013 | WO2012140680A8 Nanotori of semiconductor material for use in diagnostics and in the anti-tumor therapy and process for the production thereof |
| 01/10/2013 | WO2012138102A3 Dlk1-specific human antibodies and pharmaceutical composition containing same |
| 01/10/2013 | WO2012138100A3 Activin receptor type ii b inhibitors comprising dlk1 extracellular water-soluble domain |
| 01/10/2013 | WO2012101065A3 Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors |
| 01/10/2013 | WO2012097313A3 Therapeutic antibodies against ror-1 protein and methods for use of same |
| 01/10/2013 | WO2012096832A3 Hdac inhibiting derivatives of camptothecin |
| 01/10/2013 | WO2011111880A9 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 |
| 01/10/2013 | US20130013334 Methods for the identification, assessment, and treatment of patients with cancer therapy |
| 01/10/2013 | US20130012922 Compositions and methods for the treatment of cancer |
| 01/10/2013 | US20130012754 Microwave induced photodynamic therapy |
| 01/10/2013 | US20130012708 Heterocyclic compounds and thrombopoietin receptor activators |
| 01/10/2013 | US20130012591 Prophylaxis of skin cancer with retinamides |
| 01/10/2013 | US20130012585 Phenylacetic Acid Derivatives |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012573 Methods for intracellular delivery of nucleic acids |
| 01/10/2013 | US20130012570 GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION |
| 01/10/2013 | US20130012569 Method of treatments related to the fmr1 gene |
| 01/10/2013 | US20130012568 Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012564 SMAC Mimetic |